Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Industry: Biotechnology / Drug Discovery and Development
Curis is a drug discovery and development company focused on leveraging biological signaling pathway technologies to create new medicines, primarily for cancer. The company has no commercial products and relies on strategic collaborations with pharmaceutical partners (Genentech, Wyeth, Procter & Gamble, Ortho Biotech/Centocor) for funding and development. In 2006, Curis realigned its strategy to focus on a "Targeted Cancer Drug Development Platform" designed to create multi-target inhibitors.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Net Revenues | $14,936,000 | $6,002,000 |
| Net Loss | $(8,829,000) | $(14,855,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.18) | $(0.31) |
| Cash, Cash Equivalents & Marketable Securities | $36,656,000 | $44,209,000 |
| Working Capital | $32,521,000 | $36,010,000 |
| Total Debt (Current & Long-Term) | $1,980,000 | $5,832,000 |
| Accumulated Deficit | $(688,883,000) | $(680,054,000) |
Revenue Composition (2006):
- Research and development contracts: $9,340,000
- License and maintenance fees: $4,324,000
- Substantive milestones: $3,000,000
- Contra-revenues (co-development costs): $(1,728,000)
Material Changes vs. Prior Period
- Revenue Increase: Net revenues increased 149% to $14.9 million, driven primarily by a $3.0 million substantive milestone payment from Genentech for filing an investigational new drug application (IND) and a $2.3 million recovery of a previously written-off note receivable from Micromet AG.
- Reduced Loss: Net loss decreased by approximately $6.0 million compared to 2005, despite increased operating expenses.
- Expense Increases:
- Stock-Based Compensation: Increased significantly to $3.8 million in 2006 due to the adoption of SFAS 123(R), compared to minimal expense in 2005.
- General and Administrative (G&A): Increased 28% to $10.4 million, largely due to stock-based compensation and legal/accounting fees related to a financial restatement.
- Contra-Revenues: Decreased by $5.3 million to $1.7 million as Curis ceased its co-development participation with Genentech for a basal cell carcinoma candidate in August 2006.
- Debt Reduction: Total debt obligations decreased significantly as a convertible note to Becton Dickinson was converted into common stock in January 2006.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- Management believes existing cash resources, combined with contractually defined research funding from collaborators (Genentech through March 2007 and Wyeth through February 2008), are sufficient to fund operations into the fourth quarter of 2008.
- Future revenues are expected to be limited to amortization of license fees and contingent milestone payments, as most funded research programs are concluding.
- The company plans to advance at least one proprietary multi-target cancer program into Phase I clinical testing in 2007.
Risks and Contingencies:
- Financial Restatement: In March 2006, Curis restated financial results for 2003, 2004, and 2005 due to accounting errors regarding revenue recognition of $7.5 million in payments from Genentech. This has exposed the company to potential securities litigation.
- Liquidity: The company has never been profitable and expects to incur substantial losses. It will require additional financing to continue operations beyond late 2008.
- Collaboration Dependency: Substantially all revenue is derived from collaborators. Termination of these agreements or failure to meet milestones would severely impact operations.
- Sublease Default: A subtenant at one of Curis's facilities defaulted in August 2006, resulting in a loss of sublease income and increased facility costs.
Unusual Items:
- Micromet Recovery: Recorded $2.3 million in license fee revenue from a settlement with Micromet AG regarding a previously written-off note receivable.
- Stock-Based Compensation Adoption: The shift to fair-value accounting for stock options under SFAS 123(R) significantly increased reported expenses in 2006.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $36.7 million cash balance to fund operations through Q4 2008, considering the cessation of funded research from Genentech in early 2007.
- Restatement Impact: Assess the status of any securities litigation arising from the 2006 financial restatement and the adequacy of insurance coverage.
- Collaboration Milestones: Monitor the progress of the Genentech Phase I trial and the potential for future milestone payments, which are critical for revenue.
- Sublease Resolution: Confirm the financial impact of the 61 Moulton Street sublease default and the company's ability to mitigate lost income.
- Stock-Based Compensation: Review future stock option grant plans to estimate the ongoing impact of SFAS 123(R) on operating expenses.